Search Within

Matthew J Matasar

  1. "Radiation Oncology, Department of"
  2. "Craig Moskowitz"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (9)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. Hematologic Malignancies, Division of (20)
  4. Lymphoma (20)
  5. Radiation Oncology, Department of (20)
  6. Survivorship Research (20)

More Groups

People
  1. Craig Moskowitz (20)
  2. Joachim Yahalom (20)
  3. Alison Moskowitz (19)
  4. Andrew Zelenetz (15)
  5. Paul Hamlin (14)
  6. Anas Younes (13)

More People

Years
  1. 2023 (1)
  2. 2021 (1)
  3. 2020 (2)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (6)

More Years

Publications
  1. Blood (7)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Biology of Blood and Marrow Transplantation (2)
  5. British Journal of Haematology (1)
  6. Cancers (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. American Society of Clinical Oncology (3)
  3. Elsevier Inc. (3)
  4. Wiley Blackwell (3)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant
    Journal Article

    Vardhana, S.; Hamlin, P. A.; Yang, J.; Zelenetz, A.; Sauter, C. S.; Matasar, M. J.; Ni, A.; Yahalom, J.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Early toxicities associated with radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous stem cell transplantation (HDT-ASCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Devlin, S. M.; Yahalom, J.; Matasar, M. J.; Moskowitz, A.; Giralt, S. A.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save